Amgen reports new biosimilar data, shares in focus among healthcare peers

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 07:40.

Amgen Inc. (US0311621009) uses the current series of medical congresses to highlight new clinical and market data for its expanding biosimilar portfolio. The Nasdaq-listed biotech positions these follow-on biologics as a growth driver in immunology and oncology amid intense competition from Pfizer and Samsung Bioepis, as recent conference materials and investor communications show. Amgen investor news archive with recent biosimilar updates

Fresh biosimilar data at medical meetings

Per current materials on its investor site, Amgen reports updated data for biosimilars such as Amjevita (adalimumab-atto) and MVASI (bevacizumab-awwb) in the context of major medical meetings in 2026, including recent rheumatology and oncology congresses. These presentations emphasize real-world evidence on switching, persistence, and safety, which is crucial for hospital formularies and payer decisions. Overview of Amgen pipeline and biosimilar franchise

Amgen also highlights progress for its biosimilars targeting key reference products like Herceptin, Avastin, and Humira, underlining that these launches expand access while supporting revenue diversification away from maturing originator brands such as Enbrel. The company notes in its latest conference slide decks that the biosimilar portfolio serves both US and European markets, making it a strategic pillar for long-term growth.

Analyst focus on earnings trajectory and peers

Analyst commentary compiled in recent days points to Amgen’s earnings trajectory being closely tied to execution in its biosimilar and innovative oncology pipeline. MarketScreener and similar platforms show that several houses, including Goldman Sachs and Morgan Stanley, maintain a constructive stance on large-cap US biotech, highlighting Amgen along with peers like Gilead and Bristol Myers as core defensive holdings in healthcare. MarketScreener consensus on Amgen

Recent market reports from Reuters note that healthcare stocks on the Nasdaq have shown a relatively muted reaction to broader sector volatility, with large biotechs acting as stabilizers when cyclical segments like semiconductors swing sharply. In that context, Amgen shares are frequently cited in portfolio strategy notes as part of a balanced exposure to defensive growth and dividend income within the S&P 500 health care index. Reuters market wrap on US healthcare stocks

The product behind Amgen stock

Amgen generates revenue primarily from biologic therapies and related biosimilars, with its Humira biosimilar Amjevita being a representative product in immunology. Amjevita targets conditions such as rheumatoid arthritis and psoriasis, sold via pharmacies and specialty distributors in the US and selected international markets.

Where the Amgen stock trades

Amgen shares trade on the Nasdaq at around 300.00 US dollars as of 2026-06-26, 05:30, according to recent quote data from Nasdaq and major financial portals.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.